Venous thromboembolism in patients with surgically treated ankle fractures.


Journal

Archives of orthopaedic and trauma surgery
ISSN: 1434-3916
Titre abrégé: Arch Orthop Trauma Surg
Pays: Germany
ID NLM: 9011043

Informations de publication

Date de publication:
Mar 2023
Historique:
received: 26 07 2021
accepted: 24 09 2021
pubmed: 11 11 2021
medline: 3 3 2023
entrez: 10 11 2021
Statut: ppublish

Résumé

In patients with rotational ankle fracture, we compare the rate of venous thromboembolism development between patients who received chemoprophylaxis vs those patients that received none. Retrospective cohort study. Level I trauma center. Between 2014 and 2018, we identified 483 patients with rotational ankle fracture that had no VTE risk factors, were under 70 years of age, and had an isolated injury. Chemoprophylaxis vs no chemoprophylaxis after open reduction internal fixation of a rotational ankle fracture. Development of VTE was the primary outcome. Secondary outcomes included wound problems, infection, hematoma, or non-union. There were 313 patients that received no prophylaxis and 170 patients that received chemoprophylaxis after operative fixation of an isolated ankle fracture. Demographics including age, gender, body mass index, and ASA class were similar between groups. The rate of DVT/PE was 3.5% in those without DVT prophylaxis, and 4.1% in those on DVT prophylaxis with no significant differences found (p = 0.8). There was no significant difference in wound complication (no VTE prophylaxis-3.7% vs VTE prophylaxis-2.5%, p = 0.7) or infection rates (no VTE prophylaxis-3.8% vs VTE prophylaxis 4.1%, p = 1.0) between groups. No difference was detected in the rate of symptomatic DVT or PE in patients based on chemoprophylaxis. Our results support the conclusion that the use of chemoprophylaxis may remain surgeon preference and based on patient risk factors for VTE development. Level III-retrospective cohort study.

Identifiants

pubmed: 34757461
doi: 10.1007/s00402-021-04192-5
pii: 10.1007/s00402-021-04192-5
doi:

Substances chimiques

Anticoagulants 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1237-1242

Informations de copyright

© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Références

Goel DP, Buckley R, Devries G et al (2009) Prophylaxis of deep-vein thrombosis in fractures below the knee: a prospective randomised controlled trial. J Bone Joint Surg Br 91(3):388–394
doi: 10.1302/0301-620X.91B3.20820 pubmed: 19258618
Kock HJ, Schmit-Neuerburg KP, Hanke J et al (1995) Thromboprophylaxis with low-molecular-weight heparin in outpatients with plaster-cast immobilisation of the leg. The Lancet 346(8973):459–461
doi: 10.1016/S0140-6736(95)91320-3
Lassen MR, Borris LC, Nakov RL (2002) Use of the low-molecular-weight heparin reviparin to prevent deep-vein thrombosis after leg injury requiring immobilization. N Engl J Med 347(10):726–730
doi: 10.1056/NEJMoa011327 pubmed: 12213943
Selby R, Geerts WH, Kreder HJ et al (2015) A double-blind, randomized controlled trial of the prevention of clinically important venous thromboembolism after isolated lower leg fractures. J Orthop Trauma 29(5):224–230
doi: 10.1097/BOT.0000000000000250 pubmed: 25900749
Patterson JT, Morshed S (2017) Chemoprophylaxis for venous thromboembolism in operative treatment of fractures of the tibia and distal bones: a systematic review and meta-analysis. J Orthop Trauma 31(9):453–460
doi: 10.1097/BOT.0000000000000873 pubmed: 28459774
Zheng X, Li D-Y, Wangyang Y et al (2016) Effect of chemical thromboprophylaxis on the rate of venous thromboembolism after treatment of foot and ankle fractures. Foot Ankle Int 37(11):1218–1224
doi: 10.1177/1071100716658953 pubmed: 27521353
Selby R, Geerts WH, Kreder HJ et al (2014) Symptomatic venous thromboembolism uncommon without thromboprophylaxis after isolated lower-limb fracture: the knee-to-ankle fracture (KAF) cohort study. J Bone Jt Surg 96(10):e83
doi: 10.2106/JBJS.M.00236
Iqbal HJ, Dahab R, Barnes S (2012) UK national survey of venous thromboembolism prophylaxis in ankle fracture patients treated with plaster casts. Foot Ankle Surg 18(3):157–159
doi: 10.1016/j.fas.2011.05.004 pubmed: 22857956
SooHoo NF, Eagan M, Krenek L et al (2011) Incidence and factors predicting pulmonary embolism and deep venous thrombosis following surgical treatment of ankle fractures. Foot Ankle Surg 17(4):259–262
doi: 10.1016/j.fas.2010.08.009 pubmed: 22017898
Kadous A, Abdelgawad AA, Kanlic E (2012) Deep venous thrombosis and pulmonary embolism after surgical treatment of ankle fractures: a case report and review of literature. J Foot Ankle Surg 51(4):457–463
doi: 10.1053/j.jfas.2012.04.016 pubmed: 22632837
Shah K, Thevendran G, Younger A et al (2015) Deep-vein thrombosis prophylaxis in foot and ankle surgery: what is the current state of practice? Foot Ankle Spec 8(2):101–106
doi: 10.1177/1938640014546858 pubmed: 25205678
Stavem K, Skjaker SA, Hoel H, et al (2019) Risk factors for symptomatic venous thromboembolism following surgery for closed ankle fractures: A case-control study. Foot Ankle Surg. [Internet]. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1268773119301389 . Accessed 27 Nov 2019
Jameson SS, Rankin KS, Desira NL et al (2014) Pulmonary embolism following ankle fractures treated without an operation—an analysis using National Health Service data. Injury 45(8):1256–1261
doi: 10.1016/j.injury.2014.05.009 pubmed: 24907008
Blanco JA, Slater G, Mangwani J (2018) A prospective cohort study of symptomatic venous thromboembolic events in foot and ankle trauma: the need for stratification in thromboprophylaxis? J Foot Ankle Surg 57(3):484–488
doi: 10.1053/j.jfas.2017.10.036 pubmed: 29503135
Cancienne JM, Diduch DR, Werner BC (2017) High altitude is an independent risk factor for postoperative symptomatic venous thromboembolism after knee arthroscopy: a matched case-control study of medicare patients. Arthrosc J Arthrosc Relat Surg 33(2):422–427
doi: 10.1016/j.arthro.2016.07.031
Jones DL, Jones WA, Fleming KI et al (2019) Underdosing of prophylactic enoxaparin is common in orthopaedic trauma and predicts 90-day venous thromboembolism. J Orthop Trauma 33(11):570–576
doi: 10.1097/BOT.0000000000001563 pubmed: 31634287
Baroletti SA, Goldhaber SZ (2006) Heparin-induced thrombocytopenia. Circulation 114(8):e355–e356
doi: 10.1161/CIRCULATIONAHA.106.632653 pubmed: 16923760
Neviaser AS, Chang C, Lyman S et al (2010) High incidence of complications from enoxaparin treatment after arthroplasty. Clin Orthop Relat Res 468(1):115–119
doi: 10.1007/s11999-009-1020-6 pubmed: 19669848

Auteurs

Iain S Elliott (IS)

Department of Orthopaedics, Harborview Medical Center, Seattle, WA, USA.

Ajinkya A Rane (AA)

Kaiser Permanente San Jose Medical Center, San Jose, CA, USA.

Graham J DeKeyser (GJ)

Department of Orthopaedics, University of Utah, 590 Wakara Way, Salt Lake City, UT, 84108, USA.

Patrick J Kellam (PJ)

Department of Orthopaedics, University of Utah, 590 Wakara Way, Salt Lake City, UT, 84108, USA.

Phillip T Dowdle (PT)

Department of Orthopaedics, University of Utah, 590 Wakara Way, Salt Lake City, UT, 84108, USA.

Tommy M Safaee (TM)

Department of Orthopaedics, University of Utah, 590 Wakara Way, Salt Lake City, UT, 84108, USA.

Lucas S Marchand (LS)

Department of Orthopaedics, University of Utah, 590 Wakara Way, Salt Lake City, UT, 84108, USA.

Justin M Haller (JM)

Department of Orthopaedics, University of Utah, 590 Wakara Way, Salt Lake City, UT, 84108, USA. justin.haller@hsc.utah.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH